샘플 요청 목록

 카트 문의
시장보고서
상품코드
1782997

세계의 펩타이드 및 올리고뉴클레오티드 CDMO 시장

Peptide and Oligonucleotide CDMO
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 370 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

펩타이드 및 올리고뉴클레오티드 CDMO 세계 시장은 2030년까지 57억 달러에 달할 전망

2024년에 28억 달러로 추정되는 펩타이드 및 올리고뉴클레오티드 CDMO 세계 시장은 분석 기간인 2024-2030년에 CAGR 12.8%로 성장하여 2030년에는 57억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 펩타이드는 CAGR 14.1%를 기록하며 분석 기간 종료까지 42억 달러에 달할 것으로 예측됩니다. 올리고뉴클레오티드 분야의 성장률은 분석 기간 동안 CAGR 9.4%로 추정됩니다.

미국 시장은 7억 5,230만 달러로 추정, 중국은 CAGR 17.3%로 성장할 것으로 예측

미국의 펩타이드 및 올리고뉴클레오티드 CDMO 시장은 2024년에 7억 5,230만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 12억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 17.3%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 9.2%와 11.4%로 예측됩니다. 유럽에서는 독일이 CAGR 10.1%로 성장할 것으로 예측됩니다.

세계의 펩타이드 및 올리고뉴클레오티드 CDMO 시장 - 주요 동향과 촉진요인 정리

펩타이드 및 올리고뉴클레오티드 CDMO란?

펩타이드-올리고뉴클레오티드 개발 제조 위탁기관(CDMO)은 펩타이드와 올리고뉴클레오티드의 개발 및 제조를 전문으로 하는 기업입니다. 이들 바이오의약품은 암, 자가면역질환, 유전질환, 바이러스 감염 등 다양한 질환의 치료제 개발에 필수적입니다. 펩타이드 및 올리고뉴클레오티드 CDMO의 역할은 이러한 복잡한 분자의 연구, 개발, 대량 생산에 대한 서비스를 제공하는 것입니다. 이러한 서비스에는 일반적으로 신약 개발, 공정 개발, 제조 및 상업화 지원이 포함되어 제품이 제약 산업의 엄격한 규제 요건을 충족하도록 보장합니다.

펩타이드 의약품은 기존 저분자 의약품에 비해 특이성이 높고 독성이 낮아 큰 호응을 얻고 있습니다. 올리고뉴클레오티드는 RNA 기반 치료제 및 안티센스 올리고뉴클레오티드와 같은 제품을 포함하여 유전자 발현을 표적화하고 조절할 수 있는 능력으로 인해 점점 더 중요해지고 있습니다. 펩타이드와 올리고뉴클레오티드에 특화된 CDMO는 제약회사가 이러한 고도로 전문화된 분자를 제조하는 데 있어 어려움을 극복할 수 있도록 돕습니다. 여기에는 확장성, 순도, 수율 최적화, 규제 준수 보장 등의 과제를 극복하는 것이 포함됩니다. 펩타이드 및 올리고뉴클레오티드 기반 의약품 시장이 지속적으로 확대됨에 따라 이 분야의 CDMO 서비스 수요는 크게 증가할 것으로 예상됩니다.

펩타이드 및 올리고뉴클레오티드 CDMO 시장이 확대되는 이유는 무엇인가?

펩타이드 및 올리고뉴클레오티드 CDMO 시장은 생물학적 제제 및 맞춤형 의료의 부상, RNA 치료의 발전, 만성질환의 유병률 증가 등 몇 가지 중요한 요인에 의해 확대되고 있습니다. 가장 두드러진 촉진요인 중 하나는 생물학적 제제, 특히 펩타이드와 올리고뉴클레오티드로의 전환이 진행되고 있다는 점입니다. 이러한 생물학적 제제는 특이성이 높고, 부작용이 적으며, 희귀 유전질환, 특정 암, 바이러스 감염 등 이전에는 치료가 어려웠던 질병을 치료할 수 있습니다.

RNA 기반 치료법의 발전도 펩타이드 및 올리고뉴클레오티드 CDMO 시장의 성장에 기여하는 주요 요인 중 하나입니다. COVID-19 팬데믹에 대한 mRNA 백신의 성공은 의료 분야에서 RNA 기술의 잠재력을 부각시켰습니다. 그 결과, 올리고뉴클레오티드 제조 서비스에 대한 수요는 특히 mRNA 백신, 유전자 편집 도구, RNA 간섭 요법 등의 제품에 대한 수요가 빠르게 증가하고 있습니다. 제약회사 및 생명공학 기업들은 이러한 복잡한 분자의 제조 및 개발에 정통한 CDMO 파트너를 찾고 있습니다. 소분자 간섭 RNA(siRNA), 메신저 RNA(mRNA), 안티센스 올리고뉴클레오티드(ASO)를 포함한 올리고뉴클레오티드에 대한 수요는 RNA 치료제 연구가 확대됨에 따라 상승세를 이어갈 것으로 예상됩니다.

또한, 암, 당뇨병, 심혈관질환과 같은 만성질환의 유병률 증가로 인해 펩타이드와 올리고뉴클레오티드를 포함한 새로운 치료 접근법의 필요성이 증가하고 있습니다. 세계 인구의 고령화에 따라 이러한 질병의 근본적인 원인을 분자 수준에서 표적으로 삼는 혁신적인 의약품에 대한 수요가 증가하고 있습니다. 이에 따라 임상 및 상업화 단계에 진입하는 펩타이드 및 올리고뉴클레오티드 기반 의약품 후보물질의 수가 증가하면서 CDMO가 제공하는 전문 제조 및 개발 서비스에 대한 수요가 더욱 증가하고 있습니다.

펩타이드 올리고뉴클레오티드 CDMO의 미래를 형성하는 주요 동향은 무엇인가?

펩타이드 및 올리고뉴클레오티드 CDMO 시장의 미래는 제조 기술의 발전, 품질 및 규제 준수에 대한 중요성 증가, 확장성과 유연성에 대한 관심 증가 등 몇 가지 변화하는 추세에 의해 형성되고 있습니다. 중요한 트렌드 중 하나는 펩타이드와 올리고뉴클레오티드 합성 기술의 발전으로 보다 신속하고 효율적이며 비용 효율적인 제조 공정이 가능해졌다는 점입니다. 고체상 펩타이드 합성(SPPS), 연속 흐름 화학, 자동화 하이스루풋 시스템 등의 기술 혁신으로 고품질 펩타이드와 올리고뉴클레오티드를 대규모로 생산할 수 있는 능력이 향상되고 있으며, 이는 전 세계 수요 증가에 대응하기 위해 필수적입니다.

또한, 펩타이드와 올리고뉴클레오티드를 포함한 생물학적 제제의 규제 환경은 더욱 엄격해지고 있으며, CDMO가 품질 관리 조치를 강화하고 세계 규제 준수를 보장할 필요성이 높아지고 있습니다. 여기에는 미국 FDA나 유럽의약품청(EMA)과 같이 생물학적 제제의 개발, 제조, 유통에 대한 엄격한 가이드라인을 가지고 있는 규제기관의 요구사항을 충족하는 것도 포함됩니다. 생물학적 제제의 복잡성이 증가함에 따라 CDMO는 진화하는 규제 표준을 미리 파악하고, 제조 공정이 완벽하게 준수하고 최고 수준의 순도와 효능을 가진 치료제를 생산할 수 있도록 모범사례를 채택해야 합니다.

또 다른 중요한 트렌드는 유연하고 확장 가능한 제조 솔루션에 대한 수요 증가입니다. 펩타이드 및 올리고뉴클레오티드 기반 치료제가 임상 파이프라인을 진행함에 따라, 의약품 개발 기업들은 의약품 개발이 진행됨에 따라 확장 가능한 유연한 생산능력을 제공할 수 있는 CDMO를 필요로 하고 있습니다. 이러한 유연성은 제약회사가 비용 효율성, 품질, 규제 준수를 유지하면서 효율적으로 생산 규모를 확대할 수 있도록 하는 데 필수적입니다. 맞춤의료와 표적치료가 보편화됨에 따라 CDMO는 개별 의약품 후보물질의 고유한 니즈를 충족시킬 수 있는 맞춤형 솔루션을 제공할 수 있는 적응력을 갖춰야 할 것입니다.

펩타이드 및 올리고뉴클레오티드 CDMO 시장의 성장 촉진요인은 무엇인가?

펩타이드 및 올리고뉴클레오티드 CDMO 시장의 성장은 생물학적 제제에 대한 수요 증가, RNA 기반 치료법의 발전, 유전자 표적 치료에 대한 연구 활성화 등 여러 요인에 기인합니다. 제약 업계가 생물학적 제제로의 전환을 계속하고 있는 가운데, 펩타이드와 올리고뉴클레오티드는 더 높은 정확도와 적은 부작용으로 특정 생물학적 과정을 표적으로 삼을 수 있는 능력으로 인해 큰 주목을 받고 있습니다. 이에 따라 이러한 치료법에 초점을 맞춘 연구 개발 활동이 급증하고 있으며, 그 결과 이러한 분자의 제조 및 스케일업에 대한 전문성을 제공할 수 있는 전문 CDMO 서비스에 대한 수요가 증가하고 있습니다.

RNA 기반 치료법, 특히 mRNA 백신과 유전자 치료의 급속한 개발과 승인은 CDMO 부문의 성장을 더욱 가속화하고 있습니다. COVID-19 mRNA 백신의 성공에 이어, 보다 광범위한 질병 치료에 RNA 기술의 적용을 확대하는 것에 대한 관심이 높아지고 있습니다. 이에 따라 올리고뉴클레오티드 합성 및 RNA 생산에 있어 고도의 능력을 갖춘 CDMO에 대한 수요가 증가하고 있습니다. RNA 기반 치료제 파이프라인이 성장함에 따라, 올리고뉴클레오티드 생산 전문 CDMO는 임상시험 및 상업적 출시를 위해 생산을 확대하는 제약사를 지원할 수 있는 유리한 위치에 있습니다.

또한, 맞춤형 의료에 대한 관심이 높아짐에 따라 보다 전문적이고 소규모의 고품질 펩타이드 및 올리고뉴클레오티드 제조 서비스에 대한 수요가 증가하고 있습니다. 특정 유전자 마커나 질병 아형을 표적으로 하는 의약품의 개발이 진행됨에 따라, 높은 품질을 유지하면서 소규모의 맞춤형 배치에 대응할 수 있는 정밀 제조에 대한 중요성이 강조되고 있습니다. 유연하고 확장 가능한 고품질 제조 능력을 제공하는 CDMO는 이러한 기술 혁신을 지원하기 위해 점점 더 많은 수요가 증가하고 있습니다. 또한, 만성질환의 확산과 유전자 편집 치료로의 전환은 펩타이드 및 올리고뉴클레오티드 CDMO 시장의 확대에 기여하고 있습니다.

부문

제품 유형(펩타이드, 올리고뉴클레오티드), 서비스 유형(위탁생산 서비스, 위탁개발 서비스), 최종사용자(제약 기업 최종사용자, 바이오의약품 기업 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Agilent Technologies, Inc.
  • Ajinomoto Co., Inc.
  • Almac Group
  • Aurigene Pharmaceutical Services Ltd.
  • Bachem Holding AG
  • BioSynthesis Inc.
  • Catalent, Inc.
  • CordenPharma International
  • EUROAPI
  • GenScript Biotech Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • Merck KGaA
  • Piramal Pharma Solutions
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Senn Chemicals AG
  • STA Pharmaceutical Co., Ltd.(WuXi STA)
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec Co., Ltd.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.08

Global Peptide and Oligonucleotide CDMO Market to Reach US$5.7 Billion by 2030

The global market for Peptide and Oligonucleotide CDMO estimated at US$2.8 Billion in the year 2024, is expected to reach US$5.7 Billion by 2030, growing at a CAGR of 12.8% over the analysis period 2024-2030. Peptides, one of the segments analyzed in the report, is expected to record a 14.1% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Oligonucleotides segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$752.3 Million While China is Forecast to Grow at 17.3% CAGR

The Peptide and Oligonucleotide CDMO market in the U.S. is estimated at US$752.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Peptide and Oligonucleotide CDMO Market - Key Trends & Drivers Summarized

What Is a Peptide and Oligonucleotide CDMO and How Does It Work?

A Peptide and Oligonucleotide Contract Development and Manufacturing Organization (CDMO) specializes in the development and manufacturing of peptides and oligonucleotides, which are short chains of amino acids and nucleotides, respectively. These biopharmaceutical products are crucial in the development of therapeutics for a range of diseases, including cancer, autoimmune disorders, genetic diseases, and viral infections. The role of a peptide and oligonucleotide CDMO is to provide services related to the research, development, and large-scale production of these complex molecules. These services typically include drug discovery, process development, manufacturing, and commercialization support, ensuring that the products meet the stringent regulatory requirements of the pharmaceutical industry.

Peptide drugs are gaining significant traction due to their specificity and lower toxicity compared to traditional small-molecule drugs. Oligonucleotides, which include products like RNA-based therapeutics and antisense oligonucleotides, are becoming increasingly important for their ability to target and modulate gene expression. CDMOs focused on peptides and oligonucleotides help pharmaceutical companies navigate the challenges of producing these highly specialized molecules. This includes overcoming challenges related to scalability, purity, yield optimization, and ensuring regulatory compliance. As the market for peptide and oligonucleotide-based drugs continues to expand, the demand for CDMO services in this space is poised to increase substantially.

Why Is the Peptide and Oligonucleotide CDMO Market Expanding?

The peptide and oligonucleotide CDMO market is growing due to several key factors, including the rise of biologics and personalized medicine, advances in RNA therapies, and the increasing prevalence of chronic diseases. One of the most prominent drivers is the growing shift toward biologic drugs, particularly peptides and oligonucleotides, which are considered more targeted and precise compared to traditional small-molecule drugs. These biologics offer higher specificity, fewer side effects, and can be used to treat diseases that were previously challenging to manage, such as rare genetic disorders, certain cancers, and viral infections.

The advancement of RNA-based therapies is another major factor contributing to the growth of the peptide and oligonucleotide CDMO market. The success of mRNA vaccines in combating the COVID-19 pandemic has highlighted the potential of RNA technologies in medicine. As a result, the demand for oligonucleotide manufacturing services is rapidly increasing, particularly for products like mRNA vaccines, gene-editing tools, and RNA interference therapies. Pharmaceutical companies and biotech firms are increasingly seeking CDMO partners with expertise in the production and development of these complex molecules. The demand for oligonucleotides, including small interfering RNA (siRNA), messenger RNA (mRNA), and antisense oligonucleotides (ASOs), is expected to continue its upward trajectory as research into RNA therapeutics expands.

In addition, the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is driving the need for novel therapeutic approaches, including those involving peptides and oligonucleotides. As the global population ages, there is an escalating demand for innovative drugs that target the underlying causes of these diseases at a molecular level. This has led to a growing number of peptide and oligonucleotide-based drug candidates entering the clinical and commercial stages, further increasing the demand for specialized manufacturing and development services offered by CDMOs.

What Key Trends Are Shaping the Future of Peptide and Oligonucleotide CDMOs?

The future of the peptide and oligonucleotide CDMO market is being shaped by several transformative trends, including advances in manufacturing technologies, the increasing importance of quality and regulatory compliance, and the growing focus on scalability and flexibility. One key trend is the advancement of peptide and oligonucleotide synthesis technologies, which are enabling faster, more efficient, and cost-effective manufacturing processes. Innovations in solid-phase peptide synthesis (SPPS), continuous-flow chemistry, and automated high-throughput systems are improving the ability to produce high-quality peptides and oligonucleotides at scale, which is critical for meeting the increasing global demand.

Additionally, the regulatory environment for biologics, including peptides and oligonucleotides, is becoming more stringent, driving the need for CDMOs to enhance their quality control measures and ensure compliance with global regulations. This includes meeting the requirements set by regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA), which have strict guidelines for the development, manufacturing, and distribution of biologics. As the complexity of biologics increases, CDMOs will need to stay ahead of evolving regulatory standards and adopt best practices to ensure that their manufacturing processes are fully compliant and capable of producing therapeutics with the highest levels of purity and efficacy.

Another important trend is the growing demand for flexible and scalable manufacturing solutions. As peptide and oligonucleotide-based therapeutics move through the clinical pipeline, drug developers require CDMOs that can provide flexible manufacturing capabilities that scale with the progression of the drug’s development. This flexibility is essential as it allows pharmaceutical companies to efficiently scale up production while maintaining cost-effectiveness, quality, and regulatory compliance. As personalized medicine and targeted therapies become more common, CDMOs will also need to be adaptable in offering customized solutions that can cater to the unique needs of individual drug candidates.

What Are the Key Drivers of Growth in the Peptide and Oligonucleotide CDMO Market?

The growth in the peptide and oligonucleotide CDMO market is driven by several factors, including increasing demand for biologics, advancements in RNA-based therapies, and growing research into gene-targeted treatments. As the pharmaceutical industry continues to shift toward biologic drugs, peptides and oligonucleotides have gained significant attention due to their ability to target specific biological processes with higher precision and fewer side effects. This has led to a surge in research and development activities focused on these therapeutic modalities, thereby increasing the demand for specialized CDMO services that can provide expertise in the manufacturing and scale-up of these molecules.

The rapid development and approval of RNA-based therapies, especially mRNA vaccines and gene therapies, have further fueled growth in the CDMO sector. Following the success of mRNA vaccines for COVID-19, there has been a heightened interest in expanding the application of RNA technologies to treat a broader range of diseases. This has driven the need for CDMOs with advanced capabilities in oligonucleotide synthesis and RNA production. As the pipeline for RNA-based therapeutics grows, CDMOs that specialize in oligonucleotide manufacturing are well-positioned to support pharmaceutical companies as they scale up production for clinical trials and commercial launch.

Additionally, the increasing focus on personalized medicine is driving the need for more specialized, small-scale, high-quality peptide and oligonucleotide manufacturing services. As more drugs are developed to target specific genetic markers or disease subtypes, there is a greater emphasis on precision manufacturing that can accommodate smaller, customized batches while maintaining high levels of quality. CDMOs that offer flexible, scalable, and high-quality production capabilities are increasingly in demand to support these innovations. Moreover, the growing prevalence of chronic diseases and the shift toward gene-editing therapies are contributing to the expansion of the peptide and oligonucleotide CDMO market, as these technologies offer new avenues for treating previously untreatable conditions.

SCOPE OF STUDY:

The report analyzes the Peptide and Oligonucleotide CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Peptides, Oligonucleotides); Service Type (Contract Manufacturing Service, Contract Development Service); End-Use (Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Agilent Technologies, Inc.
  • Ajinomoto Co., Inc.
  • Almac Group
  • Aurigene Pharmaceutical Services Ltd.
  • Bachem Holding AG
  • BioSynthesis Inc.
  • Catalent, Inc.
  • CordenPharma International
  • EUROAPI
  • GenScript Biotech Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • Merck KGaA
  • Piramal Pharma Solutions
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Senn Chemicals AG
  • STA Pharmaceutical Co., Ltd. (WuXi STA)
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Peptide and Oligonucleotide CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted Therapies Propels Growth of Peptide and Oligonucleotide CDMO Services
    • Surging Investments in mRNA and RNAi Technologies Expands Addressable Market Opportunity for Oligonucleotide CDMOs
    • Advancements in Solid-Phase Peptide Synthesis (SPPS) Strengthen Business Case for Outsourcing Complex Peptides
    • Biopharma Industry's Shift Toward Outsourcing Accelerates Demand for End-to-End CDMO Partnerships
    • Expanding Applications of Peptides in Metabolic and Oncology Therapies Drives Market Penetration
    • Regulatory Encouragement for Orphan and Rare Disease Drugs Throws the Spotlight on Oligonucleotide-Based Therapies
    • Growing Pipeline of Nucleic Acid Therapeutics Spurs Long-Term CDMO Opportunities
    • Increasing Complexity of Molecule Design Generates Demand for Specialized CDMO Capabilities
    • Personalized Medicine Trends Drive Adoption of Custom Peptide and Oligo Synthesis Services
    • Emergence of Cell and Gene Therapies Expands Synergistic Opportunities for Nucleic Acid CDMOs
    • Emergence of Next-Generation Sequencing (NGS) Tools Strengthens Market for Oligonucleotide-Enabled Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Peptide and Oligonucleotide CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Contract Manufacturing Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Contract Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Biopharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제